{"id":19665,"date":"2020-03-10T21:31:17","date_gmt":"2020-03-11T01:31:17","guid":{"rendered":"https:\/\/carleton.ca\/coris\/2020\/the-michael-j-fox-foundation-target-advancement-program\/"},"modified":"2020-04-27T09:32:29","modified_gmt":"2020-04-27T13:32:29","slug":"the-michael-j-fox-foundation-target-advancement-program","status":"publish","type":"post","link":"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-target-advancement-program\/","title":{"rendered":"The Michael J. Fox Foundation \u2013 Target Advancement Program"},"content":{"rendered":"

Opportunity<\/h3>\n

The Target Advancement Program seeks to build conclusive evidence to rationalize biological targets and pathways for Parkinson\u2019s disease (PD) therapeutic development. Funding will support projects focused on validating targets and defining pathways implicated in PD pathological processes and\/or symptomology. Targets and pathways proposed for study should have a reasonable initial link to PD, such as demonstrated genetic association, altered expression\/function of the target in PD-relevant human tissue, and\/or prior clinical trial data. When considering validation studies, MJFF prioritizes applications proposing experimental systems and models with high construct validity to hypothesized pathogenic mechanisms in human PD, such as patient-derived material and\/or animal models demonstrating dysfunction in the pathway(s) proposed for study. Please note that MJFF has made significant investments in the biology of high-priority targets, including <\/span>alpha-synuclein, LRRK2, GBA and Parkin\/PINK1<\/span>. Proposals focusing on these targets will be considered on a case-by-case basis and carefully evaluated against the existing MJFF portfolio.<\/span><\/p>\n

Eligibility<\/h3>\n

Applications may be submitted by researchers or clinicians in:
\n<\/span>\u2022 <\/span>U.S. and non-U.S. biotechnology\/pharmaceutical companies, or other publicly or privately held for-profit entities; and
\n<\/span>\u2022 <\/span>U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government.
\n<\/span>\u2022 <\/span>Post-doctoral fellows are eligible to apply as co-investigators with the designation of an administrative primary investigator who directs the laboratory in which the fellow will conduct research. The administrative PI will be responsible for assisting in providing all institutional documents required for the project and will be required to sign any award contract. Training or mentoring-only proposals will not be considered.<\/span><\/p>\n

Funding Available<\/h3>\n

Up to $200,000. <\/span>R<\/span>equested support should be commensurate with work proposed. These budgets include direct and indirect costs. For academic and for-profit institutions, no more than 15% or 10%, respectively, may go to indirect costs.<\/span><\/p>\n

Internal Contacts<\/h3>\n

For proposal development\/substantive review, please contact Heloise Emdon<\/a>.<\/p>\n

Deadlines<\/h3>\n\n\n\n\n\n
Faculty Deadline<\/td>\nConsult Heloise Emdon<\/a>.<\/td>\n<\/tr>\n
OVPRI Approval Form Deadline<\/td>\nApril 16, 2020<\/td>\n<\/tr>\n
Submission to Sponsor<\/td>\nApril 23, 2020 by 5 pm (Pre-Proposal)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Submitting Your Application<\/h3>\n